Yahong Pharmaceuticals (688176.SH) released the relevant data of the APL-1401 Phase Ib clinical trial on ECC.

Zhtng Cijng APP news, Asia Rainbow Pharmaceuticals (688176.SH) announced that recently, the Phase Ib clinical trial results of APL-1401 for the treatment of moderate to severe active ulcerative colitis conducted by the company were selected for the 19th European Colorectal Congress (ECC), and the clinical data of the study were presented in the form of a poster.